CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

Peak

clindamycin phosphate

Baxter
NDAINTRAVENOUSSOLUTION
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

12.1 Mechanism of Action Clindamycin is an antibacterial drug [see ] . 12.3 Pharmacokinetics Clindamycin phosphate is a water-soluble ester prodrug of clindamycin. Biologically inactive clindamycin phosphate is converted to active clindamycin. By the end of short-term intravenous infusion, peak…

Indications (34)

the following in adultPneumococciStaphylococciserious infections caused by susceptible anaerobic bacteria in adultsserious infections due to susceptible isolates of streptococcistaphylococci in adultsserious lower respiratory tract infections including pneumoniaempyemalung abscess caused by susceptible isolates of anaerobesStreptococcus pneumoniaeother streptococci (except Eserious skinskin structure infections caused by susceptible isolates of Streptococcus pyogenesStaphylococcus aureusanaerobes in adultsserious gynecological infections including endometritisnongonococcal tubo-ovarian abscesspelvic cellulitispostsurgical vaginal cuff infection caused by susceptible anaerobes in adultsserious intra-abdominal infections including peritonitisintra-abdominal abscess caused by susceptible anaerobic organisms in adultsserious septicemia caused by susceptible isolates of Staphylococcus aureusstreptococci (except Enterococcus faecalis )susceptible anaerobes in adultsserious bonejoint infections including acute hematogenous osteomyelitis caused by susceptible isolates of Staphylococcus aureusadjunctive therapy in the surgical treatment of chronic bonejoint infections due to susceptible organisms in adultsdevelopment of drug-resistant bacteriamaintain the effectiveness of Clindamycin Phosphate in Sodium Chloride Injectionother antibacterial drugsClindamycin Phosphate in Sodium Chloride Injection should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteria

Clinical Trials (4)

NCT07205107N/ARecruiting

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Started Oct 2025
NCT03122457Phase 2Completed

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

Started Jan 2017
NCT01915732Phase 3Completed

A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris

Started Apr 2013
1,018 enrolled
Acne Vulgaris
NCT01915758Phase 1Completed

W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers

Started Nov 2008
64 enrolled
Acne Vulgaris
Company
B
Baxter
Costa Rica - Cartago
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers